MULTICENTER PHASE III BLINDED STUDY OF DAB389IL-2 IN CTCL > 4 PREVIOUS THERAPIES

这项第三阶段研究旨在评估阿司匹林的疗效和安全性 白介素2受体(IL-2R)靶向细胞毒素DAB389IL-2作为二线 皮肤T细胞淋巴瘤(CTCL)患者的治疗 既往治疗或IVA期患者遵循&gt；1既往治疗 治疗后，有复发或顽固性疾病。皮肤T细胞淋巴瘤 是T辅助者/诱导者的一组不同的恶性肿瘤 淋巴细胞亚群。在50%的病例中，这些恶性细胞表达IL-2R 免疫组织化学染色显示。

This Phase III study is designed to evaluate the efficacy and safety of an IL-2 receptor (IL-2R) targeted cytotoxin DAB389IL-2 as second line therapy in patient with cutaneous T-cell lymphoma (CTCL) who, following >4 previous therapies or stage IVa disease patients following >1 previous therapy, have recurrent or persistent disease. Cutaneous T-cell lymphoma is a heterogeneous group of malignancies of the T-helper/inducer lymphocyte subset. In 50% of cases, these malignant cells express IL-2R as demonstrated by immunohistochemical staining.